Literature DB >> 23863154

A growing role for mTOR in promoting anabolic metabolism.

Jessica J Howell1, Stéphane J H Ricoult, Issam Ben-Sahra, Brendan D Manning.   

Abstract

mTOR [mammalian (or mechanistic) target of rapamycin] is a protein kinase that, as part of mTORC1 (mTOR complex 1), acts as a critical molecular link between growth signals and the processes underlying cell growth. Although there has been intense interest in the upstream mechanisms regulating mTORC1, the full repertoire of downstream molecular events through which mTORC1 signalling promotes cell growth is only recently coming to light. It is now recognized that mTORC1 promotes cell growth and proliferation in large part through the activation of key anabolic processes. Through a variety of downstream targets, mTORC1 alters cellular metabolism to drive the biosynthesis of building blocks and macromolecules fundamentally essential for cell growth, including proteins, lipids and nucleic acids. In the present review, we focus on the metabolic functions of mTORC1 as they relate to the control of cell growth and proliferation. As mTORC1 is aberrantly activated in a number of tumour syndromes and up to 80% of human cancers, we also discuss the importance of this mTORC1-driven biosynthetic programme in tumour growth and progression.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23863154     DOI: 10.1042/BST20130041

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  95 in total

1.  When Anti-Aging Studies Meet Cancer Chemoprevention: Can Anti-Aging Agent Kill Two Birds with One Blow?

Authors:  Noriko N Yokoyama; Andria Denmon; Edward M Uchio; Mark Jordan; Dan Mercola; Xiaolin Zi
Journal:  Curr Pharmacol Rep       Date:  2015-04-14

2.  Metformin Inhibits Hepatic mTORC1 Signaling via Dose-Dependent Mechanisms Involving AMPK and the TSC Complex.

Authors:  Jessica J Howell; Kristina Hellberg; Marc Turner; George Talbott; Matthew J Kolar; Debbie S Ross; Gerta Hoxhaj; Alan Saghatelian; Reuben J Shaw; Brendan D Manning
Journal:  Cell Metab       Date:  2017-01-12       Impact factor: 27.287

3.  Involvement of mTOR in Type 2 CRF Receptor Inhibition of Insulin Signaling in Muscle Cells.

Authors:  Hongxia Chao; Haochen Li; Rebecca Grande; Vitor Lira; Zhen Yan; Thurl E Harris; Chien Li
Journal:  Mol Endocrinol       Date:  2015-04-15

4.  mTORC2 in the center of cancer metabolic reprogramming.

Authors:  Kenta Masui; Webster K Cavenee; Paul S Mischel
Journal:  Trends Endocrinol Metab       Date:  2014-05-21       Impact factor: 12.015

5.  Injury-induced decline of intrinsic regenerative ability revealed by quantitative proteomics.

Authors:  Stephane Belin; Homaira Nawabi; Chen Wang; Shaojun Tang; Alban Latremoliere; Peter Warren; Hubert Schorle; Ceren Uncu; Clifford J Woolf; Zhigang He; Judith A Steen
Journal:  Neuron       Date:  2015-04-30       Impact factor: 17.173

Review 6.  Regulation of mTORC1 by PI3K signaling.

Authors:  Christian C Dibble; Lewis C Cantley
Journal:  Trends Cell Biol       Date:  2015-07-06       Impact factor: 20.808

Review 7.  MenTORing Immunity: mTOR Signaling in the Development and Function of Tissue-Resident Immune Cells.

Authors:  Russell G Jones; Edward J Pearce
Journal:  Immunity       Date:  2017-05-16       Impact factor: 31.745

8.  Spatial control of the TSC complex integrates insulin and nutrient regulation of mTORC1 at the lysosome.

Authors:  Suchithra Menon; Christian C Dibble; George Talbott; Gerta Hoxhaj; Alexander J Valvezan; Hidenori Takahashi; Lewis C Cantley; Brendan D Manning
Journal:  Cell       Date:  2014-02-13       Impact factor: 41.582

9.  The folliculin tumor suppressor is a GAP for the RagC/D GTPases that signal amino acid levels to mTORC1.

Authors:  Liron Bar-Peled; Lynne Chantranupong; Zhi-Yang Tsun; Roberto Zoncu; Tim Wang; Choah Kim; Eric Spooner; David M Sabatini
Journal:  Mol Cell       Date:  2013-10-03       Impact factor: 17.970

10.  Emerging role of mTOR in the response to cancer therapeutics.

Authors:  Erika Ilagan; Brendan D Manning
Journal:  Trends Cancer       Date:  2016-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.